Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma

C. M. Segeren, P. Sonneveld, B. van der Holt, J. W. Baars, D. H. Biesma, J. J. Cornellissen, A. J. Croockewit, A. W. Dekker, W. E. Fibbe, B. Löwenberg, M. van Marwijk Kooy, M. H. van Oers, D. J. Richel, H. C. Schouten, E. Vellenga, G. E. Verhoef, P. W. Wijermans, S. Wittebol, H. M. Lokhorst

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

We examined the feasibility of achieving a rapid response in patients with previously untreated multiple myeloma by administering vincristine 0.4 mg and doxorubicin 9 mg/m2 as a rapid intravenous infusion for 4 d together with intermittent high-dose dexamethasone 40 mg (VAD) for remission induction treatment in patients who were scheduled to receive high-dose therapy. 139 patients (86 male, 53 female; median age 53 years, range 32-65 years; Durie & Salmon stage IIA: 42, IIB: one, IIIA: 89, IIIB: seven) were included in a prospective multicentre study in which VAD was administered as remission induction treatment and was followed by intensified treatment. The response was evaluated according to the criteria of the Eastern Cooperative Oncology Group (ECOG). The results of treatment were evaluable in 134 patients. Five patients died before evaluation. 86 patients (62%) achieved a partial response (PR) and seven patients (5%) achieved a complete response (CR), which equates to a response rate of 67%. The main side-effect was mild neurotoxicity, which was observed in 18% of the patients. Fever or infections were reported in 27% of the patients. VAD administered as an outpatient regimen, based on rapid intravenous infusion, is an effective induction regimen for untreated myeloma with a 67% response rate and acceptable toxicity
Original languageEnglish
Pages (from-to)127-130
JournalBritish Journal of Haematology
Volume105
Issue number1
DOIs
Publication statusPublished - 1999

Cite this